Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study - Wikidata - awgldk - TriplyDB

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study

http://www.wikidata.org/entity/Q35848253

about

Interventions for preventing silent cerebral infarcts in people with sickle cell disease Interventions for preventing silent cerebral infarcts in people with sickle cell disease Epidemiology and treatment of relative anemia in children with sickle cell disease in sub-Saharan Africa.Sickle cell vasoocclusion and rescue in a microfluidic device.Simultaneous acute splenic sequestration and transient aplastic crisis in children with sickle cell disease.A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG).Coinheritance of B-Thalassemia and Sickle Cell Anaemia in Southwestern Nigeria.Hydroxyurea in sickle cell disease: drug review.Translating scientific advances to improved outcomes for children with sickle cell disease: a timely opportunity.How I use hydroxyurea to treat young patients with sickle cell anemia.Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization.A combined top-down and bottom-up MS approach for the characterization of hemoglobin variants in Rhesus monkeys.Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).Pharmacotherapy in sickle cell disease--state of the art and future prospects Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?Mean Platelet Volume can Predict Cerebrovascular Events in Patients with Sickle Cell Anemia.Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.Sickle cell disease: old discoveries, new concepts, and future promise.Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.Decision analysis of treatment strategies in children with severe sickle cell disease.Fetal hemoglobin silencing in humans Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis Developmental Injury to the Cerebellar Cortex Following Hydroxyurea Treatment in Early Postnatal Life: An Immunohistochemical and Electron Microscopic Study.From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.Hydroxyurea for children with sickle cell disease The prevention and management of stroke in sickle cell anaemia.Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease A review of cis-trans interplay between DNA sequences 5' to the (G)gamma- and beta-globin genes among Hb F-Malta-I heterozygotes/homozygotes and beta-thalassemia homozygotes/compound heterozygotes, and the effects of hydroxyurea on the Hb F/F-erythr Sickle cell anemia: targeting the role of fetal hemoglobin in therapy.Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia Current management of sickle cell anemia.Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea Comparison of in-vitro and in-vivo response to fetal hemoglobin production and γ-mRNA expression by hydroxyurea in Hemoglobinopathies.Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.Growth and nutritional status of children with homozygous sickle cell disease.ENHANCE-(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease.

P2860

Q24186853-B794AA1D-B8B7-4C36-AA8F-395B1BCE2EA5 Q24200712-6A3674E7-A53E-4A7F-A23D-982147EE3C73 Q30243937-97803B6E-6132-49F6-9329-BAABCB8FDC1F Q30480917-FA9163BC-8311-4E56-A53B-C6E35CBBFE80 Q33384382-3093DC5A-2E29-4D94-B6D2-C821920EBCAC Q33440495-B9B889BC-5001-45E7-8044-80167B4B532B Q33484805-086E90FE-5A03-4F04-A2FF-DC8B48552C2F Q33556132-6407EBD1-09CB-49E1-AACA-39B2FC9F52B2 Q33619642-F00BF01A-9942-4ACC-A47B-90D4D760DD3C Q33871218-49A44A50-CB65-4767-A856-01CDCDB3A1DC Q33985120-2DC13311-D218-4BF0-AB8F-0E642029ACFA Q34026647-266EAE25-804F-4D3D-A719-F17368A6D956 Q34565638-8A639325-6124-4528-95EB-DC2719E71373 Q35036897-3080B654-9259-4F53-B643-FD566CD7C4FF Q35097294-1D601305-6E70-4800-A9DB-342A9BAD46B9 Q35220342-F20098D2-88A6-4800-8461-15D70A6C26EA Q35234959-9DA35D42-B8EC-4DA1-A5AE-D41412D38C73 Q35277610-D7F9EEF5-D51B-4F82-BE72-D59CF53B15B3 Q35525659-58FD5D2D-B93D-4CA3-8DF7-B831DF2FFA1F Q35723452-2A77938E-3636-4BBF-AF90-559E1A968A26 Q35754065-5F988D55-F12D-474D-AB11-F0A7993A528A Q35800106-BE1C4C3E-A9AA-4FE5-82E5-5B8323D50F06 Q35849129-1358F045-D471-4182-ACC4-1A9D9148C3D5 Q35951578-9464E7C7-B706-4680-8B20-397A2D66EA48 Q36124772-AFAF4224-C761-43E6-8865-005F737AB56F Q36154109-56B784CB-90FC-4FB8-9197-D504C20B790E Q36612962-DB029833-C04C-4709-9548-7F6BEAD4DE5C Q36627220-DD8800E0-E4AF-4904-B463-04CF29799E3C Q36711806-05990AEE-DBD0-438D-AD06-550EF2A1B153 Q36792555-07EA5FAA-999B-4807-822B-12DEB44D4C33 Q36814520-FAD6131B-448A-4507-9DF7-AB189FA996D4 Q36843672-458F155D-EAC5-473E-9703-35D420711D04 Q36966277-1102B2E3-1075-4617-A3FE-2C9979CAAE9B Q37040238-42E7F868-3B68-4FEC-B13F-8ED9498B979F Q37059877-FB19D0A9-0D71-4BB5-A4EC-37E8B5096D3F Q37136101-5D8D8E95-841B-4672-B769-75BAE88E9530 Q37162080-8D80BF69-32DA-45E4-B61D-A5130B24C082 Q37223344-D1965566-0768-4415-8465-22AA0F48BFA9 Q37252542-B56E25AC-1275-4A39-A130-5735A13960F2 Q37345065-5A706FEB-DA00-4680-80F6-E688C3CC1555

P2860

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study

http://www.wikidata.org/entity/Q35848253

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Long-term hydroxyurea therapy ...... ia: the HUSOFT extension study

@ast

Long-term hydroxyurea therapy ...... ia: the HUSOFT extension study

@en

type

label

Long-term hydroxyurea therapy ...... ia: the HUSOFT extension study

@ast

Long-term hydroxyurea therapy ...... ia: the HUSOFT extension study

@en

prefLabel

Long-term hydroxyurea therapy ...... ia: the HUSOFT extension study

@ast

Long-term hydroxyurea therapy ...... ia: the HUSOFT extension study

@en

P1433

Q35848253-3DC4E3DE-2B66-43D2-9985-F4430F37CAE6

P1476

Q35848253-3B56377E-7795-428C-A00B-48ED113901AD

P2093

Q35848253-4F44F2C6-A498-40A5-BE99-4DB058A68DD4

Q35848253-6FAC4B11-2AAD-415C-BECB-A503F06D46F9

Q35848253-72282315-4DCB-4378-92B7-468124485047

Q35848253-8F673A7E-E66D-40F4-91EF-2077EACBBDD8

Q35848253-A8965662-DB8F-4D54-98F2-A38A43F74ED8

Q35848253-C72AE83C-B37E-4178-9637-8EC52EC91D06

Q35848253-ED687589-55CC-4C5D-832A-6DF4CFCD6087

P2860

Q35848253-0CABD9AE-09FA-44FF-BF24-3E7AACD1BC63

Q35848253-0E5A674E-E37D-4108-8CC9-627081D28332

Q35848253-10A797EC-ACAC-4940-BDBA-C1086160B0D9

Q35848253-114E2790-2A9A-4E88-B128-0B23138CB160

Q35848253-1C7C45B6-BD70-4D94-B5BB-7C524756EA21

Q35848253-2F9645A1-79AB-4CE7-A9BD-7D7AC681D741

Q35848253-359F1366-B7AC-4AF9-BA99-F49D0ACA0601

Q35848253-35D23DEC-64BB-43F8-A793-166C44CB2B89

Q35848253-3D7621CA-13E1-4FCC-84B4-5B0624947734

Q35848253-3F0FA96C-13BB-4F22-8FC7-C9D851F4940B

P304

Q35848253-445041A8-8049-4D63-BFEA-AE96F71439CD

P31

Q35848253-F5F08D31-4733-48A0-9647-53D72808E926

P356

Q35848253-17819249-8E34-449F-982A-77C956A0ABC1

P407

Q35848253-E61365D9-0961-4B74-B130-97151CAC5B75

P433

Q35848253-6F074E6C-7AE6-4D2E-8479-5A9657EB1FFE

P478

Q35848253-A0ACECE2-557B-4F87-834D-A013A6771594

P577

Q35848253-3FB3FE9C-7576-4C46-8009-CF0694FD305B

P5875

Q35848253-A87E1F23-B73D-4CFD-8E87-DACACB951242

P698

Q35848253-E11797B8-9836-4E04-A5F9-6B10432482B9

P921

Q35848253-3534BC3A-08D5-48C9-B78B-4F8E073F7FA8

P932

Q35848253-442D0563-8343-481C-83B6-D74F4276670C

P356

BLOOD-2004-12-4973

P1433

P1476

Long-term hydroxyurea therapy ...... ia: the HUSOFT extension study

@en

P2093

J Paul Scott

http://www.w3.org/2001/XMLSchema#string

Jane S Hankins

http://www.w3.org/2001/XMLSchema#string

Lynn W Wynn

http://www.w3.org/2001/XMLSchema#string

Peter A Lane

http://www.w3.org/2001/XMLSchema#string

Russell E Ware

http://www.w3.org/2001/XMLSchema#string

Winfred C Wang

http://www.w3.org/2001/XMLSchema#string

Zora R Rogers

http://www.w3.org/2001/XMLSchema#string

P2860

Partial splenectomy in children under 4 years of age with hemoglobinopathy.

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia

Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease.

Malignancy in patients with sickle cell disease.

First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration.

Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.

Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia.

Five years of experience with hydroxyurea in children and young adults with sickle cell disease.

A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.

P304

2269-2275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2004-12-4973

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270554631

http://www.w3.org/2001/XMLSchema#string

P698

16172253

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

P932

1895275

http://www.w3.org/2001/XMLSchema#string